Immunoproliferative Disorders

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2023-04-21
Clinical Trial Update: A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 3]
A Phase 3 trial combining Zilovertamab with Ibrutinib for relapsed or refractory mantle cell lymphoma has been withdrawn.